BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. FDX
2. CBRS
3. HTZ
4. KBH
5. HON
6. TTWO
7. USO
8. MRK
9. QCOM
10. SPY

Go back to BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

BioXcel Therapeutics (BTAI) PT Raised to $84 at Canaccord Genuity

April 7, 2022 7:56 AM EDT

Canaccord Genuity analyst Sumant Kulkarni raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $84.00 (from $81.00) while maintaining a Buy rating.

The analyst commented, "Earlier today (4/6), BTAI announced that the FDA approved Igalmi (BXCL501, dexmedetomidine film) for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. We had earlier characterized approval as a... More

BioXcel Therapeutics (BTAI) PT Raised to $76 at Jefferies

April 6, 2022 11:40 AM EDT

Jefferies analyst Chris Howerton raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $76.00 (from $73.00) while maintaining a Buy rating on FDA Approval of IGALMI Sublingual Film.

The analyst noted the label was broad, pricing is soon, and trade-launch in Q3.

... More